The pivotal event in this decision is DNA end resection, the enzymatic trimming of the 5-prime strands at the break to generate single-stranded DNA tails. If resection proceeds, the cell is effectively committed to homologous recombination, because the single-stranded overhangs become coated with the RPA protein and later with RAD51, which searches for homologous sequence on the sister chromatid. If resection is blocked, the ends remain available for the Ku70-Ku80 heterodimer, which recruits the DNA-dependent protein kinase catalytic subunit and the ligase complex that carries out classical non-homologous end joining. Resection is therefore not merely a step in one repair route; it is the molecular switch that determines which route is taken, and its regulation is correspondingly elaborate.

Resection unfolds in two phases. Short-range processing is initiated by the MRE11-RAD50-NBS1 complex, known as MRN, whose nuclease activity is stimulated by the phosphorylated cofactor CtIP. MRN makes an internal incision near the break and removes the blocking Ku protein, a step that single-molecule imaging studies have illuminated in striking detail. Long-range resection then extends the single-stranded tracts over thousands of nucleotides through two principal routes: one driven by the nuclease EXO1, and the other by the helicase-nuclease pair BLM or WRN working with DNA2. These pathways, first defined in budding yeast through the Sgs1-Dna2 and Exo1 systems, are conserved in human cells, where the RecQ helicases cooperate with DNA2 to process breaks and stalled replication forks alike.

Standing athwart this machinery is a famous antagonism between two tumor-suppressive and genome-protective forces: the BRCA1-BARD1 complex and the 53BP1 axis. 53BP1 is recruited to breaks by marks laid down by the RNF8 and RNF168 ubiquitin ligases, and it recognizes dimethylated histone H4 lysine 20 together with ubiquitinated H2A lysine 15 on damaged nucleosomes. Once bound, 53BP1 recruits RIF1 and the shieldin complex, which protect DNA ends and actively counteract resection, in part through CST-Pol-alpha-primase-mediated fill-in synthesis that restores paired ends. Bunting and colleagues showed in 2010 that loss of 53BP1 restores homologous recombination in BRCA1-deficient cells, establishing that these two pathways act in direct opposition at the same breaks.

Recent biochemical work has sharpened the picture of how BRCA1-BARD1 wins this contest in the appropriate cellular context. Two 2024 studies in Nature demonstrated that BRCA1-BARD1 directly stimulates EXO1-dependent and BLM-DNA2 or WRN-DNA2 long-range resection, while also protecting stalled replication forks from excessive nuclease degradation. The BARD1 subunit reads the H2AK15 ubiquitin mark and unmethylated H4K20 characteristic of newly replicated chromatin, which explains why the complex is preferentially recruited to breaks in the S and G2 phases of the cell cycle, when a sister chromatid is available as a template. BRCA1 also promotes the removal of 53BP1 from damage sites and accelerates CtIP-mediated resection, tipping the balance decisively toward homologous recombination precisely when the template-based pathway is feasible and safest.

The review also emphasizes an emerging layer of regulation involving RNA. Transient RNA-DNA hybrids, or R-loops, form at double-strand breaks and are required for efficient repair, yet their persistence is dangerous: accumulated hybrids interfere with resection and homologous recombination and can promote chromosomal translocations. Helicases such as senataxin, DDX5, DHX9 and the DEAD-box protein DDX1, together with RNase H enzymes recruited by BRCA2, resolve these structures at the right time. Remarkably, RNA transcripts can also stimulate repair directly: the discovery of DR-loops, three-stranded intermediates containing both DNA-DNA and RNA-DNA pairing, showed that RNA can help guide the homology search, and recent work suggests RNA transcripts may even serve as templates for repair in human cells, particularly in post-mitotic neurons where sister chromatids are unavailable.

Why does all this matter for medicine? The clearest example is PARP inhibitor therapy, built on the synthetic lethality between BRCA1 or BRCA2 deficiency and inhibition of poly(ADP-ribose) polymerase, a concept demonstrated in landmark 2005 studies and now a mainstay of treatment for BRCA-mutated breast, ovarian, pancreatic and prostate cancers. Tumors frequently escape by restoring the homologous recombination pathway without fixing the original BRCA mutation. Loss of 53BP1, or of its effectors such as RIF1, shieldin components, REV7 or the CST complex, releases the brake on resection and rescues BRCA1-deficient cells from PARP inhibitor sensitivity. Longitudinal profiling of patients has revealed that reversion mutations in BRCA1 and BRCA2 can co-occur with alterations in TP53BP1, RIF1 and PAXIP1, revealing polyclonal and mechanistically diverse routes to drug resistance within the same patient.

The pathway-choice framework also points to new therapeutic vulnerabilities. Homologous-recombination-deficient tumors depend on polymerase theta, an enzyme that mediates an alternative end-joining route, and first-in-class Pol-theta inhibitors have now entered development as potential synthetic lethal partners alongside PARP inhibitors. Conversely, understanding how the CST complex, through its subunits CTC1, STN1 and TEN1, directly blocks both EXO1 and BLM-DNA2 resection suggests that nuclease inhibition is a second, independent mechanism by which cells protect DNA ends, one that operates at telomeres and at replication-coupled breaks as well as at damage-induced double-strand breaks. Each of these nodes is a potential drug target or biomarker in its own right.

What emerges from this synthesis is a picture of repair pathway choice as a dynamic, multi-layered decision governed by cell-cycle position, chromatin state, the availability of a homologous template, the enzymatic machinery assembled at the break, and even the RNA molecules transcribed nearby. The authors caution that despite concerted efforts by many laboratories, the field is only beginning to appreciate the mechanisms that underpin the choice between homologous recombination and end joining. As those mechanisms come into focus, they are increasingly legible in the clinic: in the genetic signatures of PARP inhibitor resistance, in biomarkers such as 53BP1 expression that predict treatment response, and in the design of the next generation of therapies that exploit the repair weaknesses cancer cells cannot hide.

Subject of Research: Mechanisms governing the choice between homologous recombination and non-homologous end joining in DNA double-strand break repair and their relevance to cancer and therapeutic resistance.

Article Title: Mechanisms and disease relevance of DNA break repair pathway choice

Article References: Swift, M. L., Rogers, C. M., Kaur, H., Chowdhury, D., & Sung, P. (2026). Mechanisms and disease relevance of DNA break repair pathway choice. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-026-01026-3

Image Credits: AI Generated

DOI: 10.1038/s41580-026-01026-3

Keywords: DNA double-strand breaks, homologous recombination, non-homologous end joining, DNA end resection, BRCA1-BARD1, 53BP1, shieldin, PARP inhibitors, R-loops, genome stability, synthetic lethality, drug resistance

The review, published on 26 August 2026 by Xinyan Zou, Botao Zhang, Binxian Gu, Yong Gong, Yanchao Bai and Likui Zhang, focuses on NurA as a central component of a compact DNA end-resection machine. In archaeal cells, NurA works together with the HerA helicase and the Mre11-Rad50 complex. Their combined task is to process the broken ends of DNA and generate single-stranded DNA tails with a free 3′ end. These tails are essential substrates for homologous recombination, a repair pathway that uses an intact DNA molecule as a template to restore missing genetic information.

The first challenge after a double-strand break is not simply joining the broken ends. For homologous recombination to begin, the cell must carefully reshape the damaged DNA. One strand is progressively removed from each broken end, exposing the complementary strand as single-stranded DNA. This directional process, known as end resection, creates a molecular platform on which recombination proteins can assemble. The resulting 3′ single-stranded tails are particularly important because they can search for and pair with a matching sequence in an undamaged chromosome. NurA appears to perform a major part of the enzymatic cutting required to produce these tails, while HerA helps unwind the DNA and Mre11-Rad50 contributes to the initial recognition and processing of the break.

Structurally, archaeal NurA forms a toroidal dimer, producing a ring-shaped molecular assembly with a central channel. This architecture is more than a visual feature. A ring-shaped nuclease can help confine DNA within a defined catalytic environment, positioning the nucleic acid for controlled cleavage as it passes through or interacts with the channel. The dimeric arrangement also creates an extended surface for DNA binding and may help coordinate the movement of DNA with the action of the associated HerA helicase. According to the review, NurA and HerA can form a continuous channel, suggesting that DNA may be transferred directly from the helicase into the nuclease without freely diffusing into the surrounding cell.

NurA possesses two related but distinct catalytic capabilities. It can act as a 5′-to-3′ exonuclease, removing nucleotides sequentially from a DNA end, and it can also function as an endonuclease, cutting within a DNA strand rather than only at its terminus. These activities provide the enzyme with flexibility during repair. Exonucleolytic digestion can enlarge a resected region from an existing DNA end, while endonucleolytic cleavage may help initiate processing at particular DNA structures or positions. The balance between the two activities is likely to depend on the DNA substrate, the arrangement of the protein complex and the presence of partner enzymes, although the review emphasizes that important mechanistic questions remain unresolved.

The chemical engine behind NurA’s activity is a divalent metal ion. In particular, manganese ions, or Mn²⁺, are described as essential for catalysis. Like many nucleases, NurA is thought to use metal ions to organize the DNA substrate, activate water molecules and stabilize the negatively charged reaction intermediates that form when phosphodiester bonds are broken. The requirement for Mn²⁺ highlights the importance of the enzyme’s catalytic environment: without the appropriate metal cofactor, the chemical steps needed to cleave DNA cannot proceed efficiently. The review also summarizes the identification of amino acids that contribute to DNA binding and strand cleavage, helping define how NurA recognizes its substrate and positions the scissile phosphate bond for hydrolysis.

The NurA–HerA partnership is particularly significant because it links two physically different operations: DNA unwinding and DNA degradation. HerA is a helicase that uses energy from nucleotide hydrolysis to separate the two strands of the DNA duplex. NurA, positioned alongside it, can then process the exposed strand. Their continuous channel offers a possible explanation for how archaeal cells coordinate these reactions while minimizing the risk of uncontrolled DNA degradation. Rather than allowing a nuclease and helicase to operate independently, the paired system could guide DNA through a protected molecular corridor in which unwinding and resection are synchronized. The Mre11-Rad50 complex adds another layer of coordination by participating in the detection and early processing of broken chromosome ends.

This compact repair system is also important from an evolutionary perspective. NurA homologs are found across archaeal lineages and in some bacteria, but no NurA counterpart is known in eukaryotes. At the same time, eukaryotic cells possess more elaborate DNA end-resection pathways that perform related functions through different protein assemblies. The presence of NurA in archaea, together with its partnership with HerA and Mre11-Rad50, raises questions about how ancient DNA repair strategies were reorganized during the transition from prokaryotic ancestors to the first eukaryotic cells. The review presents NurA as a potentially valuable molecular marker for tracing which parts of double-strand break repair machinery were retained, replaced or lost during evolution.

Particular attention is drawn to the Asgard superphylum, a group of archaea considered especially relevant to studies of eukaryotic origins. Genomic surveys have identified widespread, previously uncharacterized NurA homologs in Asgard archaea. These proteins could reveal whether the structural and catalytic features observed in other archaeal NurA enzymes were already present in lineages related to the ancestors of eukaryotes. However, the review makes clear that Asgard-derived NurA proteins have not yet been experimentally characterized. Their biochemical activities, metal requirements, oligomeric states and interactions with HerA or Mre11-Rad50 remain open questions. Sequence similarity alone cannot establish whether these proteins possess the same dual nuclease activities or assemble into comparable DNA-processing channels.

The authors therefore identify structural biology and biochemistry as priorities for the next stage of research. Determining the three-dimensional structures of Asgard NurA proteins, ideally in complexes with DNA, HerA and metal ions, could show whether their active sites and central channels resemble those of previously studied archaeal enzymes. Complementary experiments could measure their exonuclease and endonuclease activities, define their substrate preferences and test how mutations in DNA-binding or catalytic residues affect repair-related reactions. Reconstituting the NurA–HerA–Mre11-Rad50 system outside the cell would be especially informative because it could reveal how each component contributes to end resection and whether the proteins form a stable, coordinated machine. By connecting molecular structure with biochemical function and evolutionary distribution, NurA research may help explain how cells across the domains of life learned to repair broken chromosomes—and why some lineages ultimately replaced this ancient strategy with entirely different molecular solutions.

Subject of Research: Archaeal NurA nuclease and its role in DNA double-strand break repair

Article Title: Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair

Article References: Zou, X., Zhang, B., Gu, B. et al. “Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair.” Applied Microbiology and Biotechnology (2026). https://doi.org/10.1007/s00253-026-14009-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00253-026-14009-3

Keywords: NurA nuclease; Archaea; DNA double-strand break repair; HerA helicase; Mre11-Rad50; homologous recombination; DNA end resection; Mn²⁺-dependent nuclease; Asgard archaea; molecular evolution